Welcome to our dedicated page for Church & Dwight Co SEC filings (Ticker: CHD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Church & Dwight Co., Inc. (NYSE: CHD) brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including current reports on Form 8‑K and other key documents. Church & Dwight describes itself in these filings as a Delaware corporation with principal offices in Ewing, New Jersey, operating as a manufacturer and marketer of personal care, household and specialty products and as the leading U.S. producer of sodium bicarbonate.
Investors researching CHD can use this page to access Form 8‑K filings that report material events, such as quarterly earnings announcements, strategic portfolio actions, and governance changes. Recent 8‑Ks reference press releases announcing financial results for quarters ended June 30 and September 30, 2025, a definitive agreement to sell the VitaFusion and L’il Critters vitamin brands (including related trademarks, licenses and facilities) to Piping Rock Health Products, Inc., and an amendment to the company’s Corporate Governance Guidelines removing limits on board tenure while maintaining an age‑based retirement requirement.
Alongside 8‑Ks, users can locate annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and other filings that provide detail on Church & Dwight’s brand portfolio, segment reporting for its consumer domestic, consumer international and specialty products businesses, and risk factors and accounting policies described by the company. These documents also reflect information about capital structure, dividend practices and board‑level decisions disclosed to regulators.
Stock Titan enhances access to these filings with AI‑powered summaries that highlight the main points of lengthy reports, helping readers quickly understand earnings discussions, portfolio transactions, governance updates and other topics covered in CHD’s SEC submissions. Real‑time updates from EDGAR, combined with simplified explanations of 10‑K and 10‑Q content and visibility into insider‑related filings such as Form 4, allow users to review Church & Dwight’s regulatory record in a structured, accessible format.
Lee B. McChesney, EVP and Chief Financial Officer of Church & Dwight Co., Inc. (CHD), reported a transaction dated 08/08/2025 showing an acquisition of 5,409 shares at $91.375 per share, leaving him with 5,409 shares following the reported transaction. The Form 4 also includes entries tied to restricted stock units (RSUs) granted earlier in the year.
The filing describes two RSU grants dated 03/24/2025: one for 1,600 RSUs that vest in three equal annual installments beginning 03/24/2026, and another for 20,580 RSUs that vest in two equal annual installments beginning 03/24/2026. Each RSU converts 1-for-1 into common stock upon vesting and is subject to the reporting person’s continued employment.
Church & Dwight (CHD) Form 4 filing: EVP International Michael Read purchased 2,000 CHD common shares on 08/05/2025 in an open-market transaction (Code P) at an average price of $91.27 per share, investing roughly $182.5 k. Following the trade, Read directly owns 7,505 shares and indirectly holds 1,400 shares through his spouse’s pension plan. No derivative security activity was reported.
Church & Dwight (CHD) posted weaker Q2 25 results. Net sales were nearly flat at $1.51 bn (-0.3 % YoY) but gross margin fell 420 bps to 42.9 %, reflecting $30.4 m inventory and fixed-asset impairment tied to the planned exit of Flawless, Spinbrush and Waterpik showerhead lines. Operating income dropped 22 % to $261.7 m and diluted EPS declined to $0.78 from $0.99.
For 1H 25, revenue slipped 1.4 % to $2.97 bn while net income slid 13 % to $411.1 m; diluted EPS was $1.66 (vs. $1.91). Cash from operations contracted 17 % to $416.5 m, pressured by a $186 m working-capital build (mainly lower accrued marketing and payables). CHD still closed the half with $923 m cash and $2.21 bn long-term debt.
Segment mix shifted: Consumer Domestic sales dipped 1.4 % but International rose 5.3 %; Specialty Products Division fell 3 %. Depreciation & amortization was $117.5 m YTD; amortization expense is expected to run ~$104 m for FY 25.
Capital allocation: In May the company launched a $300 m accelerated share repurchase (2.8 m shares already received) under its evergreen program; $659 m remains authorized. Dividends paid YTD totaled $145 m ($0.59/sh).
Subsequent events (post-quarter): 1) $700 m Touchland acquisition (hand-sanitizer brand) with up to $180 m earn-out; majority of purchase price expected to be assigned to the trade name. 2) New $2.0 bn revolving credit agreement (option to $2.75 bn) maturing 2030, replacing prior $1.5 bn facility.
Management is also conducting a strategic review of the vitamins business after a 2024 impairment and is addressing tariff exposure (~$60 m annualised) via supply-chain actions and selective price increases.